Neurological Sciences最新文献

{"title":"Tremors with dystonia as a predominant manifestation of primary coenzyme Q10 deficiency.","authors":"Ashish Sharma, Sahil Mehta, Jagdeep Singh, Vivek Lal","doi":"10.1007/s10072-025-08126-6","DOIUrl":"https://doi.org/10.1007/s10072-025-08126-6","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sonographic follow up for brachial plexopathy after a pacemaker implantation.","authors":"Berkay Yalçınkaya, Ahmet Furkan Çolak, Hilmi Berkan Abacıoğlu, Levent Özçakar","doi":"10.1007/s10072-025-08117-7","DOIUrl":"https://doi.org/10.1007/s10072-025-08117-7","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of uric acid in Parkinson's disease: a UK brain bank pathology-validated case-control study.","authors":"Lazzaro di Biase, Pasquale Maria Pecoraro, Simona Paola Carbone, Vincenzo Di Lazzaro","doi":"10.1007/s10072-025-08112-y","DOIUrl":"https://doi.org/10.1007/s10072-025-08112-y","url":null,"abstract":"<p><strong>Introduction: </strong>Uric acid has been supposed to have a protective role in Parkinson's disease with controversial findings. This relationship has not been validated with pathology-confirmed diagnoses. This study aims to compare uric acid levels between pathology-confirmed and clinically-misdiagnosed Parkinson's disease patients over time.</p><p><strong>Methods: </strong>65 patients with an in-vivo clinical diagnosis of Parkinson's disease were enrolled from the UK Brain Bank. 33 were confirmed with post-mortem pathology analysis, while 32 were clinically misdiagnosed patients. Chart review explored uric acid levels at two timepoints (NO and N1). A repeated-measures ANOVA evaluated uric acid level variation over time and determined differences between the groups, including timespan between samples, disease duration, age at death, age of onset and sex as covariates.</p><p><strong>Results: </strong>Average uric acid levels at N0 were 5.83 mg/dl (SD ± 1.99) and 5.94 mg/dl (SD ± 1.87) for respectively true and false positives. At N1, the values were 7.61 mg/dl (SD ± 2.35) and 7.36 mg/dl (SD ± 2.86) for respectively true and false positives. A significant main effect of time on uric acid levels was found (F(1, 58) = 4.303, p = 0.042, η²_p = 0.069). The interaction between time and the covariates was not significant, suggesting that these variables did not influence uric acid level variation over time. No influence of the diagnostic confirmation and covariates on uric acid levels between groups was found.</p><p><strong>Conclusion: </strong>While uric acid levels increase over time in Parkinson's disease patients, this increase does not differ significantly between those with confirmed and unconfirmed diagnoses, nor it is influenced by disease duration, age at death, age of onset or sex.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prominent and fast response to eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis.","authors":"Christian Messina, Laura Basile, Grazia Crescimanno, Salvatore Battaglia, Nicola Scichilone, Filippo Brighina, Vincenzo Di Stefano","doi":"10.1007/s10072-025-08128-4","DOIUrl":"https://doi.org/10.1007/s10072-025-08128-4","url":null,"abstract":"<p><strong>Introduction: </strong>Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease caused by antibodies against the postsynaptic membrane at the neuromuscular junction, leading to muscle weakness, fatigue, and respiratory failure in severe cases. Myasthenic crisis (MC) is a life-threatening condition which requires hospitalization and treatments with intravenous immunoglobulin, plasma exchange and high dose steroids. We report a case of a patient with refractory MC and anti-AChR antibodies positivity who started Eculizumab as rescue therapy, leading to a complete resolution of the acute neuromuscular condition.</p><p><strong>Case presentation: </strong>A 72-year-old man presented with bilateral ptosis, severe weakness in all limbs, dysphonia, dysphagia and dyspnea. He was diagnosed with MG with anti-AChR positivity and refractory MC. He was unresponsive to classical rescue therapy, so he underwent Eculizumab administration which resulted in a notable improvement in symptoms.</p><p><strong>Discussion: </strong>Eculizumab, a humanized monoclonal antibody that inhibits complement activation, is now approved as treatment for refractory generalized MG with anti-AChR antibodies. The use of eculizumab in refractory MC is still under investigation; however, this case report suggests that it could be a promising treatment option for patients with severe acute clinical condition.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccines for Alzheimer's disease: a brief scoping review.","authors":"Ibrahim Serag, Mohamed Abouzid, Mostafa Hossam El Din Moawad, Jaber H Jaradat, Mohamed Hendawy, Nada Ibrahim Hendi, Ibraheem M Alkhawaldeh, Judy Ahmed Abdullah, Mona Mahmoud Elsakka, Muneeb Ahmad Muneer, Marwa Aboelhassan Elnagar, Mohamed Adel Fakher, Aya J Elkenani, Abdallah Abbas","doi":"10.1007/s10072-025-08073-2","DOIUrl":"https://doi.org/10.1007/s10072-025-08073-2","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia among older adults. Existing treatments-such as cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and monoclonal antibodies targeting amyloid beta-can improve functional and neuropsychiatric outcomes but fail to prevent disease onset, halt progression, or adequately reduce amyloid-beta burden. Consequently, research efforts have shifted to primary prevention through immunization, although the efficacy of these strategies remains uncertain. This review explores the efficacy, safety, and adverse events of current immunotherapies for AD and discusses future research and clinical implications.</p><p><strong>Methods: </strong>A scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-SR) checklist. A systematic search was carried out using PubMed, Scopus, and Web of Science.</p><p><strong>Results: </strong>A total of 145 studies were included. Preclinical research often employed transgenic mouse models to investigate AD pathology and vaccine benefits, while Phase I and II clinical trials centered on safety and preliminary efficacy in humans. Most studies were conducted in the USA, China, and Japan, highlighting these countries' strong clinical trial infrastructure. Vaccination frequently reduced amyloid-beta or tau pathology in preclinical settings, although cognitive outcomes were inconsistent. Clinical trials primarily focused on safety and immune response, with newer vaccines such as ABvac40 demonstrating encouraging results and minimal adverse events.</p><p><strong>Conclusion: </strong>Although AD vaccines show promise in preclinical settings, longer and more comprehensive clinical trials are necessary to determine their long-term efficacy and safety. Standardized protocols and efforts to reduce regional disparities in research would facilitate better comparability and generalizability of findings, thereby guiding the future development of effective immunotherapies for Alzheimer's disease.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of intravenous thrombolysis in patients with mild acute ischemic stroke and large vessel occlusion with different hypoperfusion volumes.","authors":"Kechun Chen, Min Liu, Wenjun Zhang, Zhengduo Li, Huimin Shi","doi":"10.1007/s10072-025-08109-7","DOIUrl":"https://doi.org/10.1007/s10072-025-08109-7","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate early treatment strategies for patients with mild acute ischemic stroke and large vessel occlusion, we evaluated the efficacy of intravenous thrombolysis in patients with mild stroke and large vessel occlusion in different hypoperfusion volumes.</p><p><strong>Methods: </strong>Cohort data of consecutive patients (October 2021 to June 2024) with anterior circulation large vessel occlusion mild stroke (NIHSS ≤ 5) with onset < 24 h were retrospectively analyzed. We compared the outcomes of patients treated with intravenous thrombolysis (IVT) and dual antiplatelet therapy (DAPT). The outcomes of patients on IVT and DAPT were then compared between the large-volume hypoperfusion group (> 65 ml) and the small-volume hypoperfusion group (≤ 65 ml) based on the hypoperfusion volume of CT perfusion (Tmax > 6s).</p><p><strong>Results: </strong>A total of 222 patients were enrolled in the study (62 IVT, 160 DAPT). In 111 patients with small-volume hypoperfusion, there was no statistically significant difference in the rate of good prognosis (mRS0-1) at 90 days, the rate of early neurological deterioration and the rate of intracranial hemorrhage between the IVT and DAPT groups (P > 0.05). In another 111 patients with large-volume hypoperfusion, the IVT group had a higher rate of good prognosis (mRS0-1) at 90 days (OR:3.639,95%CI:1.249 ~ 10.601, P:0.018) and a higher rate of intracranial hemorrhage (OR:11.029, 95%CI:1.015 ~ 119.873, P:0.049) compared to the DAPT group.</p><p><strong>Conclusions: </strong>In mild acute ischemic stroke patients with large-volume hypoperfusion and large-vessel occlusion, IVT has a higher rate of intracranial hemorrhage but a higher proportion of excellent functional outcomes compared with DAPT. Further randomized controlled trials are needed.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ditans and Gepants: hope or false promise for menstrual migraine?","authors":"Gonçalo Cabral","doi":"10.1007/s10072-025-08121-x","DOIUrl":"https://doi.org/10.1007/s10072-025-08121-x","url":null,"abstract":"<p><p>Menstrual migraine (MM) is a debilitating migraine subtype associated with hormonal fluctuations, often resistant to conventional treatments. Gepants, novel calcitonin generelated peptide (CGRP) receptor antagonists, and ditans, serotonin 5-HT1F receptor agonists, offer potential alternatives to triptans due to their non-vasoconstrictive properties. However, evidence supporting their effectiveness in MM remains limited. While studies suggest gepants may reduce perimenstrual migraine severity and ditans provide acute relief, their overall efficacy compared to triptans remains uncertain. Cost and side effect profiles further complicate their widespread adoption. This letter discusses the current state of evidence for gepants and ditans in MM, highlighting the need for further large-scale, real-world studies to clarify their role in treatment strategies.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electric massage chair-induced cervical spinal epidural hematoma.","authors":"Xiaowen Qiu, Xinping Bu, Xiaoyu Qiu","doi":"10.1007/s10072-025-08116-8","DOIUrl":"https://doi.org/10.1007/s10072-025-08116-8","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NfL as a biomarker in ATTRv amyloidosis: potential and limitations.","authors":"Massimo Russo, M De Luca, L Gentile, F D'Arma, A Pugliese, V Macaione, F Polito, L Licitri, A Cafarchio, M H Aguennouz, C Rodolico, A Mazzeo","doi":"10.1007/s10072-025-08110-0","DOIUrl":"https://doi.org/10.1007/s10072-025-08110-0","url":null,"abstract":"<p><p>Hereditary transthyretin amyloidosis (ATTRv) presents unique challenges in diagnosis and monitoring due to its phenotypic and genetic heterogeneity. This study evaluates the utility of serum neurofilaments light chains (NfL) as a reliable biomarker of disease activity in patients carrying different pathogenic TTR variants. Twenty-eight ATTRv patients carrying the following mutations (p.Phe84Leu, p.Glu109Gln, p.Thr69Ala, p.Val50Met) as well as 8 carriers and 27 healthy control subjects underwent extensive examination, including serum NfL measurement, neuropathy impairment score for the lower limb (NIS-LL), compound autonomic dysfunction test (CADT), and polyneuropathy disability (PND) scores, at T0, T6 and T12. The study not only confirms the previously established correlation between serum NfL concentrations and disease severity scales but also extends these observations to the mutations reported here. Furthermore, the research highlights the potential of serum NfLs as discriminators between presymptomatic carriers and symptomatic patients, emphasizing their utility in predicting disease onset and facilitating timely intervention.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stress hyperglycemia indexes and early neurological deterioration in spontaneous intracerebral hemorrhage.","authors":"Carmelo Tiberio Currò, Federica Ferrari, Giovanni Merlino, Stefan Moraru, Francesco Bax, Fedra Kuris, Lorenzo Nesi, Mariarosaria Valente, Elena Ballante, Nicola d'Altilia, Cristina Rascunà, Andrea Morotti, Federico Mazzacane, Anna Maria Cavallini","doi":"10.1007/s10072-025-08097-8","DOIUrl":"https://doi.org/10.1007/s10072-025-08097-8","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the relationship of early neurological deterioration (END) with admission glycemia (aG) and new stress hyperglycemia indexes in spontaneous intracerebral hemorrhage (ICH) patients.</p><p><strong>Methods: </strong>The present retrospective study included 171 ICH patients from two stroke centers. END was defined as an increase ≥ 4 points in National Institutes of Health Stroke Scale and/or a decrease ≥ 2 points in Glasgow Coma Scale within 72 hours from admission. The included stress hyperglycemia indexes were glycemic gap (GGAP), stress hyperglycemia ratio (SHR), and glucose-glycated hemoglobin ratio. GGAP was calculated as aG - 28,7*glycated hemoglobin + 46,7; SHR as aG / (28,7*glycated hemoglobin - 46,7); Glucose-glycated hemoglobin ratio as aG / glycated hemoglobin. We performed univariate and multivariate analyses for END. The receiver operating characteristic curves were built for END-related glycemic measures; area under curves (AUC) were calculated and compared. The optimized threshold values were calculated, and significant glycemic measures were dichotomized. Univariate and multivariate analyses were performed for the dichotomized measures.</p><p><strong>Results: </strong>END was present in 21 patients (12.3%) and was significantly associated with GGAP, SHR and glucose-glycated hemoglobin ratio, but not with aG. The AUC of the three stress hyperglycemia indexes did not differ significantly. The optimized cutoffs were 35.68 (sensitivity 0.47, specificity 0.81), 1.15 (sensitivity 0.62, specificity 0.68), and 26.67(sensitivity 0.43, specificity 0.80) for GGAP, SHR, and glucose-glycated hemoglobin ratio respectively. END was also associated with all stress hyperglycemia indexes expressed as categorical variables.</p><p><strong>Conclusion: </strong>GGAP, SHR, and glucose-glycated hemoglobin ratio were predictors of END in ICH patients.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}